Back to search

The University of Edinburgh

Burdens and outcomes of paediatric-onset inflammatory bowel disease in regional, national and pan-UK cohorts

Abstract

dc:description.abstract

BACKGROUND: Inflammatory bowel disease (IBD) comprising Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBDU) is a chronic condition affecting people globally; a significant proportion of patients present in childhood and adolescence and the incidence and prevalence of paediatric IBD (PIBD) is reported to be rising worldwide. It is a complex condition, multifactorial in origin, with genetics, environment, immunity and infection all contributing. Common genetic architecture is shared with other autoimmune diseases, which are known to cluster within families and individuals, and available treatment options also overlap; this includes the biological agents which inhibit TNF (anti-TNFα agents). Patients diagnosed in childhood and adolescence in most countries are cared for in paediatric services before moving to adult services at an appropriate time for lifelong care; this move is either by transfer of information only or as part of a transition process involving 1 or more joint clinic appointments involving the patient, their parents/carers, their current PIBD clinical team and the adult IBD team taking over their care. AIMS: This thesis aims to use cohort studies at different geographical levels to investigate the following: 1.The outcomes of a Scottish regional (South East Scotland) cohort of PIBD patients around the time of transition from paediatric to adults services 2.The prevalence of one or more additional autoimmune diseases (AIDs) in a Scotland-wide cohort of PIBD patients 3.The real-life experience of biological therapy (anti-TNF) use in a UK-wide cohort of PIBD patients METHODS: Transition cohort – data were collected locally of patients identified as having discharged from paediatric to adult services 2007-2013 via a database kept primarily for service development and delivery; comparing status at time of transfer and last adult follow-up (LAFU). Autoimmune diseases cohort – data were collected from all 4 Scottish PIBD centres (Aberdeen, Dundee, Edinburgh, Glasgow) after identification from an incident and prevalent research cohort with previous recruitment via full informed consent. Biological therapy cohort – data collected and held by the Royal College of Physicians as part of the IBD biological therapy audit, submitted by local clinicians, of PIBD patients newly commenced on biological therapy from 09/2011 to 02/2014. RESULTS: Transition cohort – Of 138 patients who transferred to adult services, pan-treatment exposure (to all commonly available therapies at the time of data collection) rose significantly from 12% at transfer to 27% at LAFU (p=0.006) and pan-treatment refractory disease from 4% at transfer to 19% at LAFU (p=0.001). 37% of all PIBD patients had one or more IBD related surgical procedure by LAFU, with 22% of CD patients requiring at least one procedure by time of transfer. Sixty percent of patients who miss ≥1 appointment in the year prior to transfer go on to miss appointments in the year post transfer compared to 21% (15/73) who had no missed appointments pre-transfer; this was statistically significant (p=0.00001). Thirty-one percent of those who missed appointments pre-transfer were lost to follow-up at the end of the study compared to 11% with no missed appointments (p=0.005). Fifteen percent of patients overall had significant psychological +/or social comorbidity during the study period, the commonest issues were depression, deliberate self-harm and anxiety. Autoimmune diseases cohort – Of 809 patients in the cohort, 6.4% (52/809) had an additional diagnosis of an associated autoimmune disease; 3 patients had multiple co-morbid AIDs in addition to IBD. Autoimmune liver disease in 37% was the most frequently occurring co-morbid AID, followed by psoriasis (23%), then juvenile idiopathic arthritis (JIA 17%). Biological therapy cohort – Of 524 patients newly started on biological therapy, the response to induction was recorded in just 17% (89/524); of those 75% had a positive response and 60% achieved remission. In 2287 infusions and 302 years of patient follow-up, acute infusion reactions were reported in just 2% of initial (and 1% of follow-up) infliximab infusions and with no adalimumab treatments. Patient reported outcome measures were poorly utilised. CONCLUSIONS: PIBD patients have a significant clinical and therapeutic burden of disease within paediatric services which continues to progress in adulthood. A significant proportion of PIBD patients are lost to follow-up in adult services; patients who miss appointments prior to transfer appear to be more at risk for this and may benefit from a targeted approach. Clinicians should be vigilant to the possible co-existence of additional autoimmune diseases in PIBD patients and actively monitor liver function and extra-intestinal signs and symptoms. Biological therapy appears to be safe and effective in real-world practice but the response to induction is poorly documented and this risks inappropriate continuation of therapy or inadequate drug monitoring; the need for improvement is highlighted.

Degree

thesis:*
Grantor dc:publisher
The University of Edinburgh
Year dc:date.issued
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Merrick, Victoria May-Wan
Advisors dc:contributor.advisor
  • Wilson, David
  • Satsangi, Jack

Subjects

dc:subject × 3

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Edinburgh
Base URL
era.ed.ac.uk/server/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Merrick, Victoria May-Wan. Burdens and outcomes of paediatric-onset inflammatory bowel disease in regional, national and pan-UK cohorts. The University of Edinburgh, 2023. https://hdl.handle.net/1842/40737